No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
No Data
Sihuan Pharmaceutical's 2024 Loss Widens 301%
SIHUAN PHARM (00460.HK) announced its annual results, with sales revenue from the medical beauty Business increasing by approximately 65.4%.
On March 17, Glonghui announced that SIHUAN PHARM (00460.HK) achieved total revenue of approximately RMB 1901.1 million for the fiscal year ending December 31, 2024, reflecting an increase of about 2.2% year-on-year. Revenue from the medical beauty Business was approximately RMB 744.2 million, up about 65.4% year-on-year, mainly due to the high market recognition of products during the year, which significantly boosted medical beauty sales revenue, alongside new income generated from product sales. Revenue from Innovative Drugs and Other Pharmaceuticals was approximately RMB 57.6 million, up about 388.1% year-on-year.
The performance of SIHUAN PHARM (00460.HK) shows that the loss widened to 0.217 billion yuan last year, and no dividend will be distributed.
SIHUAN PHARM (00460.HK) announced its full-year results for the year ended December last year, with a revenue of 1.901 billion yuan (RMB), an increase of 2.2% year-on-year. The loss widened to 0.217 billion yuan, compared to a loss of 54.017 million yuan in the same period last year; loss per share was 2.34 cents. No dividends were declared.
SIHUAN PHARM: ANNOUNCEMENT OF ANNUAL RESULTS FOR THE YEAR ENDED 31 DECEMBER 2024
Domestic Innovative Drugs are once again surging towards overseas markets! Concept stocks have responded with a significant increase. Is the external authorization model the optimal choice?
① As of the time of publication, the Hang Seng Innovative Drugs Index has risen over 5%, with multiple Innovative Drugs concept stocks experiencing double-digit gains; ② In recent days, Jiangsu Hengrui Pharmaceuticals, Hepo Pharmaceutical, UNITED LAB, and other Biotech companies have issued announcements about "going abroad"; ③ Northeast Securities stated that top MNCs recognize the R&D capabilities of Chinese local companies and are more willing to assign high valuations.
Are profit turning points starting to appear? The Sector for Innovative Drugs in Hong Kong stocks is strengthening, and the annual reports show that many pharmaceutical companies have entered a performance harvesting period.
① The Innovative Drugs Sector in Hong Kong stocks has risen across the board, what Bullish factors are worth paying attention to? ② Annual reports show that multiple pharmaceutical companies have entered a performance harvest period, does this indicate that a profit turning point is approaching?
